Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728382 | 0.99 | POLB (0.49) | POLBADRB1DNMT1TK2ABL1 | |
| SCHEMBL17304819 | 0.94 | POLB (0.46) | POLBADRB1DNMT1 | |
| SCHEMBL38653997 | 0.91 | POLB (0.45) | POLBADRB1DNMT1ABL1RIN1 | |
| SCHEMBL30238601 | 0.87 | PLA2G1B (0.52) | POLB | |
| SCHEMBL17522659 | 0.86 | POLB (0.47) | POLBADRB1DNMT1ABL1RIN1 | |
| SCHEMBL16281862 | 0.86 | POLB (0.47) | POLBADRB1DNMT1ABL1RIN1 | |
| SCHEMBL21011276 | 0.86 | POLB (0.56) | POLBADRB1DNMT1TK2ABL1 | |
| SCHEMBL22942033 | 0.86 | POLB (0.56) | POLBADRB1DNMT1TK2ABL1 | |
| SCHEMBL3627002 | 0.86 | POLB (0.56) | POLBADRB1DNMT1TK2ABL1 | |
| SCHEMBL3626999 | 0.86 | POLB (0.56) | POLBADRB1DNMT1TK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681897-B1 | N4-MODIFIED CYTIDINE NUCLEOTIDES AND THEIR USE | UNIV VILNIUS (LT) | 2025-05-14 | — | — | EP | disclosed |
| US-11584772-B2 | N4-modified cytidine nucleotides and their use | VILNIUS UNIVERSITY (LT) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584772-B2 | N4-modified cytidine nucleotides and their use | PNP, RNGTT, ADA | POLB 100/4885ADRB1 3856/4885DNMT1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.